Navigation Links
REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
Date:5/28/2008

> Time: 2-6 p.m.

Location: S Hall A1

Poster Number: 42H Abstract Number: 8053

Presenter: Naiyer A Rizvi, MD

Monday, June 2

-- XL647 (EGFR, HER2, VEGFR2) - Poster & Discussion

"Activity and tolerance of XL647 in NSCLC patients with acquired

resistance to EGFR-TKIs: Preliminary results of a phase 2 trial"

Day: Monday, June 2

Session: Lung Cancer -- Metastatic

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-12:15 p.m. Location: W375d

Poster Number: 9 Abstract Number: 8028

Presenter: Vincent A. Miller, MD

-- XL880* (MET, VEGFR2) -- Poster

"Preliminary activity of GSK1363089 (XL880), a dual MET/VEGFR2

inhibitor, in MET amplified poorly differentiated gastric cancer

(PDGC): Interim results of a multicenter phase 2 study"

Day: Monday, June 2

Session: Gastrointestinal (Noncolorectal) Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 33D Abstract Number: 4572

Presenter: Minaxi P. Jhawer, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, p
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
2. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
3. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
4. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
5. Exelixis Announces Closing of Public Offering of Common Stock
6. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
7. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
8. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
9. Exelixis Sells 80% Stake in Artemis to Taconic
10. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
11. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Mathematic studies at the Program for ... funded by the Jeffrey Epstein VI Foundation , have ... visually identified for elimination. These aggressive cells are the driver ... a topological map of what to look for when examining ... while tumor cells can be extracted from biopsy, it,s very ...
(Date:8/21/2014)... Sofia, Bulgaria (PRWEB) August 21, 2014 ... was released today by Ontotext . Now ... and semantic analysis of structured and unstructured data is ... of the cost of enterprise technology. Organizations that do ... approaches for data management can use S4 since there ...
(Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... ROCKVILLE, Md., Jan. 9, 2012  Neuralstem, Inc. (NYSE Amex: ... Richard Garr will present at the 2012 Biotech Showcase ... Garr will serve on the Therapeutic Focus Panel entitled, ... Alliance for Regenerative Medicine (ARM) Insight Track. Garr will ...
... WOBURN, Mass., Jan. 9, 2012 Advanstar|CBI recently announced ... and Access Programs. The Forum takes place March 6-7, ... includes leading experts from Eli Lilly, Genentech, AstraZeneca, Shire ... Patient Assistance Pavilion participant Needy Meds recently interviewed PAP,s ...
... Jan. 9, 2012   Veracyte, Inc ., a ... molecular cytology, today announced that Palmetto GBA, a ... coverage for the company,s Afirma Gene Expression Classifier ... that Veracyte,s genomic test is now accessible to ...
Cached Biology Technology:Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase 2Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase 3Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis 2Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis 3
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
(Date:8/20/2014)... pregnant teenagers in Rochester, NY, nearly half engaged in ... cornstarch, vacuum dust, baby powder and soap, and other ... such teens had significantly lower iron levels as compared ... Pregnant teens, regardless of pica, are at higher risk ... and anemia. Low iron in pregnant teens raises the ...
(Date:8/20/2014)... are visible in in this image of the Para ... these were most likely intentionally set in order to ... forest or stand of trees where the land is ... include conversion of forestland to farms, ranches, or urban ... green of the Amazon Rainforest in the middle of ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Pica in pregnant teens linked to low iron 2
... trees that once characterized expansive tracts of tropical rainforest ... Just how big a role these winged gardeners play ... at Chicago and several Latin American universities are about ... laboratory in Mexico's gulf coast state of Veracruz. , ...
... plants such as corn, soybeans and sunflowers into fuel ... biodiesel generates, according to a new Cornell University and ... energy benefit to using plant biomass for liquid fuel," ... Cornell. "These strategies are not sustainable." , Pimentel and ...
... structural details of a family of mysterious objects called ... of bacteria. The discovery was published Aug. 5 in ... at how microcompartments are built, and what the pieces ... chemistry and biochemistry, and a member of the UCLA-DOE ...
Cached Biology News:Birds and bats sow tropical seeds 2Birds and bats sow tropical seeds 3Ethanol and biodiesel from crops not worth the energy 2New discovery blurs distinction between human cells and those of bacteria 2New discovery blurs distinction between human cells and those of bacteria 3
synphilin-1 (V-19)...
... contains the basic components required for the ... and recombinant canine Monocyte Chemotactic Protein 1 ... Each kit contains sufficient materials to run ... that the following conditions are met:2 ...
... MaV203 Competent Yeast Cells are designed for ... 1). S. cerevisiae strain MaV203 contains deletions ... for use with GAL4-based two-hybrid systems. The ... for selection of ProQuest bait and prey ...
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
Biology Products: